Paclitaxel loaded nanosponges: In-vitro characterization and cytotoxicity study on MCF-7 cell line culture

Current Drug Delivery

Volumn 8, Issue 2, 2011, Pages 194-202

  Ansari, Khalid A ^a,b   Torne, Satyen J ^a   Vavia, Pradeep R ^a   Trotta, Francesco ^b   Cavalli, Roberta ^b  

^a UNIVERSITY OF MUMBAI   (India)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Complexation; Cyclodextrin; Cytotoxicity; Nanosponges; Paclitaxel

Indexed keywords

BETA CYCLODEXTRIN; NANOPARTICLE; NANOSPONGE; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; FOURIER TRANSFORM MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; NANOSTRUCTURES; OSMOLAR CONCENTRATION; PACLITAXEL; PARTICLE SIZE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 79551649572     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111794479934     Document Type: Article

References (24)

1. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formula-tions. Int. J. Pharm., 2002, 235,179-192.
2. Straubinger, R.M.; Sharma, A.S.; Murray, M.; Mayhew, E. Novel Taxol formulations:Taxol-containing liposomes. J. Natl. Cancer Inst. Monogr., 1993, 15, 69-78.
3. Weiss, R.B.; Weiss, R.C.; Donehower, P.H.; Wiernik, T.; Ohnuma, R.J.; Gralla, D.L.; Trump, J.R.; Baker, J.R. Hypersensitivity reac-tions from Taxol. J. Clin. Oncol.,1990, 8, 1263-1268.
4. Simamora, P.; Dannenfelser, R.; Tabibi, S.E.; Yalkowsky, S.H. Emulsion formulations for intravenous administration of paclitaxel. J. Pharm. Sci. Tech., 1998, 52,170-172.
5. Sharma, U.S.; Balasubramanian, S.V.; Straubinger, R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci., 1995, 84, 1223-1230.
6. Pace, S.N.; Pace, G.W.; Parikh, I.; Mishra, A.K. Novel injectable formulations of insoluble drugs. Pharm. Technol., 1999, 23, 116-134.
7. Hite, M.; Turner, S.; Federici, C. Part 1: Oral delivery of poorly soluble drugs. Pharm. Manuf. Packing. Sourcer Autumn., 2003, 38-40.
8. Cavalli, R.; Trotta, F.; Tumiatti, W. Cyclodextrin-based nano-sponges for drug delivery. Incl. Phenom. Macrocycl.Chem., 2006, 56, 209-213.
9. Trotta, F.; Tumiatti, W. Cross-linked polymers based on cyclodextrin for removing polluting agents. World patent WO 03/085002, 2003.
10. Vavia, P.R.; Swaminathan, S.; Trotta, F.; Torne, S.J. Formulation of beta cyclodextrin based nanosponges of itraconazole. Incl. Phenom. Macrocycl.Chem., 2007, 57(1-4), 89-94.
11. Swaminathan, S.; Pastero, L.; Serpe, L.; Troota, F.; Vavia, P.; Aquilano, D.; Trotta, M.; Zara, G.; Cavalli, R. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eur. J. Pharm. Biopharm., 2009, 74, 193-201.
12. Torne, S.J.; Ansari K.A.; Vavia, P.R.; Trotta, F.; Cavalli, R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanoaponges. Drug. Deliv., 2010, 17(6), 419-425
13. Yang, X.H.; Sladek, T.L.; Liu, X.; Butler, B.R.; Froelich, C.J.; Thor, A.D. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin and etoposide-induced apoptosis. Cancer Res., 2001, 61, 348-354.
14. O'Brien, E.P.; Moyna, G. Use of 13C chemical shift surfaces in the study of carbohydrate conformation. Application to cyclomaltooligosaccharides (cyclodextrins) in the solid state and in solution. Carbohydr. Res., 2004, 339, 87-96.
15. Schneider, H.J.; Hacket, F.; Ru D.V. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev., 1998, 98, 1755-1786.
16. Orlowski, S.; Garrigos, M. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer. Res., 1999, 19, 3109-3124.
17. Fromm, M.F. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Phar-macol. Ther., 2002, 38(2), 69-74.
18. Hunter, J.; Hirst, B.H. Intestinal secretion of drugs. The role of P- glycoprotein and related drug efflux systems in limiting oral drug adsorption. Adv. Drug. Deliv. Rev., 1997, 25, 129-157.
19. Sikic, B.I.; Fisher, G.A.; Lum, B.L.; Halsey, J.; Chen, G. Modula-tion and prevention of multidrug resistance by inhibitors of P- glycoprotein. Cancer Chemother. Pharmacol., 1997, 40, S13-S19.
20. Asperen, J.V.; Tellingen, O.V.; Beijnen, J.H. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol. Res., 1998, 37(6), 429-435.
21. Terwogt, J.M.M.; Malingre, M.M.; Beijnen, J.H.; Ten, Bokkel, Huinink, W.W.; Rosing, H.; Koopman, F.J.; van, Tellingen, O.; Swart, M.; Schellens, J.H.M. Coadministration of oral cyclosporine A enables oral therapy with paclitaxel. Clin.Cancer. Res., 1999, 5, 3379-3384.
22. Zhang, Y.; Benet, L.Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40, 159-168.
23. Sonnichsen, D.S.; Hurwitz, C.A.; Pratt, C.B.; Shuster, J.J.; Relling, M.V. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J. Clin. Oncol., 1994, 12, 532-538.
24. Wang, S.; Monagle, J.; Mcnulty, C.; Putnam, D.; Chen, H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J. Pharm. Sci., 2004, 93(11), 2755-2767.